HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.

Abstract
Thrombopoietin receptor agonists, which raise platelet counts in patients with chronic immune thrombocytopenia, may be associated with increases in bone marrow (BM) reticulin. Patients with chronic immune thrombocytopenia participating in the Eltrombopag Extended Dosing (EXTEND) study underwent BM biopsies to identify clinically relevant BM fibrosis-related increases. Specimens were centrally reviewed by 2 hematopathologists. Two hundred thirty-two biopsy specimens were collected from 117 patients treated for ≤5.5 years. Moderate to marked reticulin fibrosis was found in 2 patients. After withdrawing from the study, the biopsy of 1 patient reverted to normal. There were no other pathologic changes identified among on-treatment specimens, and no pattern of abnormal reticulin deposition associated with eltrombopag treatment was evident.
AuthorsRussell K Brynes, Attilio Orazi, Dickens Theodore, Paul Burgess, Christine K Bailey, Maung M Thein, Kalpana K Bakshi
JournalAmerican journal of hematology (Am J Hematol) Vol. 90 Issue 7 Pg. 598-601 (Jul 2015) ISSN: 1096-8652 [Electronic] United States
PMID25801698 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© 2015 Wiley Periodicals, Inc.
Chemical References
  • Benzoates
  • Hydrazines
  • Pyrazoles
  • Receptors, Thrombopoietin
  • Reticulin
  • eltrombopag
Topics
  • Adult
  • Benzoates (administration & dosage, adverse effects)
  • Bone Marrow (drug effects, pathology)
  • Bone Marrow Examination
  • Chronic Disease
  • Female
  • Follow-Up Studies
  • Humans
  • Hydrazines (administration & dosage, adverse effects)
  • Male
  • Middle Aged
  • Platelet Count
  • Primary Myelofibrosis (diagnosis, etiology, pathology)
  • Purpura, Thrombocytopenic, Idiopathic (drug therapy, pathology)
  • Pyrazoles (administration & dosage, adverse effects)
  • Receptors, Thrombopoietin (antagonists & inhibitors)
  • Reticulin (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: